Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 5/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.48 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.39 |
| ▸ | ACP1 | P24666 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3202146 | 1.00 | CYP1A1 (0.48) | CYP1A1CYP1B1PPARGPPARAPPARD | |
| SCHEMBL27737215 | 0.88 | CYP1A1 (0.47) | CYP1A1CYP1B1PPARGKDM4EHTT | |
| SCHEMBL3207356 | 0.86 | PPARG (0.53) | CYP1A1CYP1B1PPARGPPARAPPARD | |
| SCHEMBL3207364 | 0.86 | PPARG (0.53) | CYP1A1CYP1B1PPARGPPARAPPARD | |
| SCHEMBL3217734 | 0.82 | PPARG (0.68) | CYP1A1CYP1B1PPARG | |
| SCHEMBL3217717 | 0.82 | PPARG (0.68) | CYP1A1CYP1B1PPARG | |
| SCHEMBL27737221 | 0.76 | PPARG (0.52) | CYP1A1CYP1B1PPARGPPARAPPARD | |
| SCHEMBL3206915 | 0.75 | PPARG (0.69) | CYP1A1CYP1B1PPARGPPARAPPARD | |
| SCHEMBL3206898 | 0.75 | PPARG (0.69) | CYP1A1CYP1B1PPARGPPARAPPARD | |
| SCHEMBL3213635 | 0.74 | MAPT (0.45) | CYP1A1CYP1B1KDM4EKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| EP-1912645-A2 | THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
| WO-2007018314-A2 | THERAPEUTIC AGENT FOR DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | CYP1A1 2809/4885CYP1B1 2548/4885PPARG 31/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | CYP1A1 2059/4885CYP1B1 2202/4885PPARG 30/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | CYP1A1 2809/4885CYP1B1 2548/4885PPARG 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.